Guanhao Biotech Co.,Ltd. (SHE:300238)
China · Delayed Price · Currency is CNY 10.95
+0.65 (6.31%)
Nov 6, 2026, 9:25 AM CST
Guanhao Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 329.95 | 372.84 | 363.52 | 388.8 | 361.02 | 462.6 |
Other Revenue | 14.91 | 14.91 | 13.97 | 15.38 | 16.27 | 26.38 |
| 344.85 | 387.75 | 377.48 | 404.18 | 377.29 | 488.98 | |
Revenue Growth | -12.21% | 2.72% | -6.60% | 7.13% | -22.84% | 11.91% |
Cost of Revenue | 86.79 | 90.57 | 78.83 | 88.26 | 159.6 | 125.38 |
Gross Profit | 258.06 | 297.18 | 298.65 | 315.92 | 217.69 | 363.6 |
Selling, General & Admin | 199.59 | 218.15 | 214.63 | 221.9 | 210.31 | 242.05 |
Research & Development | 39.07 | 40.97 | 36.16 | 44.5 | 50.52 | 46.62 |
Other Operating Expenses | 5.83 | 6.08 | 4.04 | 3.15 | 3.03 | 4.07 |
Operating Expenses | 244.95 | 266.72 | 263.39 | 276.27 | 272.77 | 295.44 |
Operating Income | 13.11 | 30.46 | 35.26 | 39.65 | -55.08 | 68.16 |
Interest Expense | -1.23 | -4.04 | -1.03 | -1.78 | -4.11 | -7.36 |
Interest & Investment Income | 1.91 | 2.56 | 1.27 | 1.5 | 2.22 | 2.19 |
Currency Exchange Gain (Loss) | 0.17 | 0.17 | -0.12 | -3.52 | -2.34 | 0.58 |
Other Non Operating Income (Expenses) | -1.74 | 0.06 | 0.24 | -4.11 | 1.11 | -5.8 |
EBT Excluding Unusual Items | 12.22 | 29.22 | 35.62 | 31.74 | -58.2 | 57.77 |
Impairment of Goodwill | - | - | - | - | -214.33 | -0.15 |
Gain (Loss) on Sale of Investments | -0.15 | - | -10.84 | -3.64 | -41.36 | -4.68 |
Gain (Loss) on Sale of Assets | 0.09 | -0.01 | 0.03 | 0.92 | 0.03 | 0.33 |
Asset Writedown | 1.12 | -0.08 | -4.98 | -0.29 | -3.61 | -0.05 |
Other Unusual Items | -3 | -1.86 | 8.19 | 3.35 | 24.9 | 28.83 |
Pretax Income | 10.28 | 27.28 | 28.02 | 32.09 | -292.58 | 82.06 |
Income Tax Expense | 9.15 | 12.49 | 11.41 | 11.02 | 35.06 | 31.32 |
Earnings From Continuing Operations | 1.13 | 14.79 | 16.61 | 21.07 | -327.64 | 50.74 |
Minority Interest in Earnings | 12.44 | 9.56 | 10.81 | 9.93 | 19.81 | 22.95 |
Net Income | 13.57 | 24.35 | 27.42 | 31.01 | -307.82 | 73.69 |
Net Income to Common | 13.57 | 24.35 | 27.42 | 31.01 | -307.82 | 73.69 |
Net Income Growth | -48.39% | -11.20% | -11.58% | - | - | 58.14% |
Shares Outstanding (Basic) | 269 | 271 | 274 | 258 | 265 | 263 |
Shares Outstanding (Diluted) | 269 | 271 | 274 | 258 | 265 | 263 |
Shares Change | 1.25% | -1.33% | 6.11% | -2.63% | 0.83% | 1.66% |
EPS (Basic) | 0.05 | 0.09 | 0.10 | 0.12 | -1.16 | 0.28 |
EPS (Diluted) | 0.05 | 0.09 | 0.10 | 0.12 | -1.16 | 0.28 |
EPS Growth | -49.03% | -10.00% | -16.67% | - | - | 55.56% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | -19.78 | 33.3 | -26.65 | 0.23 | 29.81 | 117.68 |
Free Cash Flow Per Share | -0.07 | 0.12 | -0.10 | 0.00 | 0.11 | 0.45 |
Gross Margin | 74.83% | 76.64% | 79.12% | 78.16% | 57.70% | 74.36% |
Operating Margin | 3.80% | 7.85% | 9.34% | 9.81% | -14.60% | 13.94% |
Profit Margin | 3.94% | 6.28% | 7.26% | 7.67% | -81.59% | 15.07% |
Free Cash Flow Margin | -5.74% | 8.59% | -7.06% | 0.06% | 7.90% | 24.07% |
EBITDA | 33.62 | 51 | 55.85 | 61.16 | -31.56 | 94.51 |
EBITDA Margin | 9.75% | 13.15% | 14.79% | 15.13% | -8.37% | 19.33% |
D&A For EBITDA | 20.51 | 20.54 | 20.59 | 21.51 | 23.52 | 26.35 |
EBIT | 13.11 | 30.46 | 35.26 | 39.65 | -55.08 | 68.16 |
EBIT Margin | 3.80% | 7.85% | 9.34% | 9.81% | -14.60% | 13.94% |
Effective Tax Rate | 89.01% | 45.80% | 40.73% | 34.33% | - | 38.17% |
Revenue as Reported | 94.27 | 387.75 | 377.48 | 404.18 | 377.29 | 488.98 |
Advertising Expenses | - | 10.89 | 10.97 | 12.39 | 9.43 | 15.72 |